Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Pradaxa Bleeding Problems May Be More Dangerous, Frequent Than Xarelto or Eliquis: Report September 29, 2015 Irvin Jackson Add Your Comments While reports of uncontrollable bleeding have been linked to all medications that are part of a new class known as novel oral anticoagulants, a drug safety report suggests that side effects of Pradaxa may be far more dangerous than those associated with its competitors, Xarelto and Eliquis. According to the latest QuaterWatch report (PDF) issued by the Institute for Safe Medication Practices (ISMP), which analyzes adverse event reports submitted to the FDA last year, incidents involving Pradaxa bleeding problems are twice as likely to involve death. Xarelto (rivaroxaban) had the largest number of adverse event reports, according to ISMP, but it also had many more prescriptions, and still did not equal the number of serious injuries linked to Pradaxa (dabigatran). Learn More About Pradaxa Internal Bleeding Lawsuit Side effects of Pradaxa may increase risk of severe bleeding and death. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Pradaxa Internal Bleeding Lawsuit Side effects of Pradaxa may increase risk of severe bleeding and death. Learn More SEE IF YOU QUALIFY FOR COMPENSATION “In overall serious reports in the U.S., [Pradaxa] had the largest number,” according to the comparison of adverse events described by ISMP. “After adjusting for differences in exposure, the difference with the more widely dispensed [Xarelto] was still greater, 14.1 serious injury reports per 1,000 person-years for [Pradaxa], compared to 6.6 for [Xarelto], and 4.4 for [Eliquis]. Examining the severity of the reported cases, the mortality rate for [Pradaxa] events, at 20.9% was about double that for the other two drugs.” In 2014, there were 3,592 serious adverse event reports involving Pradaxa, with 752 involving the death of the patient. That compares to 3,331 reports linked to Xarelto bleeding problems, with 379 involving a patient death, and 1,014 Eliquis serious event reports that involved 108 deaths. Once sales numbers are factored in to the evaluation, the number of Pradaxa problems stands out even more. Xarelto dominated the novel oral anticoagulant market in the fourth quarter of 2014, with 1,758,016 prescriptions filled. Eliquis came in second with 609,301 prescriptions. Pradaxa, however, was the weakest selling of the three drugs, with only 560,887 prescriptions, and yet it still outpaced the other drugs in serious adverse events and deaths. Novel Oral Anticoagulant Bleeding Concerns All three drugs were developed to replace warfarin for the prevention of strokes in patients with nonvalvular atrial fibrillation, and also for use in preventing blood clots following hip and knee replacement surgery for at-risk populations. However, warfarin still dominates the market, with more than 80 million prescriptions in the fourth quarter of 2014 alone. Ironically, despite the introduction of the new competitors meant to replace it, warfarin sales were at their highest since 2008, according to the ISMP report. Warfarin, also sold under the brand name Coumadin, must be carefully dosed to patients, with blood monitoring required as often as every two weeks. The new drugs, Xarelto, Eliquis and Pradaxa, have been promoted as not needing that testing, and thus being easier to use. While all blood thinners carry a risk of bleeding events and hemorrhaging, warfarin users can be given a dose of vitamin K to reduce its blood-thinning effects. However, there are no such reversal agents available yet for Pradaxa, Xarelto or Eliquis. Even against warfarin, however, ISMP found that Pradaxa appeared to be more dangerous, while the report found that Xarelto was less effective at preventing strokes. “The odds of a death outcome for [Pradaxa] compared to warfarin were nearly 3 times higher after adjusting for patient age, the share of direct reports, and concomitant therapy with other blood-clot-inhibiting drugs,” the report notes. “For [Xarelto], embolic-thrombotic events (treatment failure) compared to warfarin were more likely to be reported, after adjustment for patient age and other clot-inhibiting medication.” The ISMP reports that there are things that could be done to reduce the risk of bleeding events with the new blood thinners, but those steps are not being taken in the United States, including the use of platelet inhibitors. “The FDA has not taken action to reduce the bleeding risks of [Pradaxa] through making a lower dose available for older patients, and blood level tests to identify patients with sub-therapeutic or unusually high blood levels,” the report notes. “These risk-reduction tools are available in Europe, Canada, and elsewhere.” More than 4,000 Pradaxa lawsuits have been filed by users of that drug who suffered bleeding injuries. Following several years of litigation, Boehringer Ingelheim ultimately agreed to pay $650 million in Pradaxa settlements, with an average of about $150,000 per claim. However, the drug maker continues to face new Pradaxa claims brought by individuals who have experienced bleeding problems since the settlement. A growing number of Xarelto lawsuits and Eliquis lawsuits are also being filed throughout the U.S. Estimates suggest that that Xarelto litigation will ultimately include many more cases than the Pradaxa litigation, as the drug has become more widely used in recent years. Tags: Bleeding, Blood Thinners, Boehringer Ingelheim, Coumadin, Eliquis, Hemorrhage, Pradaxa, Stroke, Warfarin, Xarelto Image Credit: | More Pradaxa Lawsuit Stories Jury Awards $540K in Pradaxa Trial Against Boehringer Ingelheim May 21, 2019 Paragard IUD Lawsuit Dismissed on Summary Judgment February 25, 2019 Boehringer Ingelheim Ordered to Pay $1.25M For Failure to Warn About Pradaxa Bleeding Risks October 25, 2018 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermEmailThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Lawsuit Alleges Depo-Provera DMPA Injection Increases Brain Tumor Risks (Posted: 2 days ago) A Depo-Provera lawsuit blames the active ingredient, DMPA, for an increased risk of the development of brain tumors. MORE ABOUT: DEPO-PROVERA LAWSUITOrtho-Cept, Similar Birth Control Pills Linked to Intracranial Meningioma Risks, Study Warns (06/17/2025)Status of Depo-Provera Shot Lawsuits Outlined by MDL Judge (06/13/2025)Pfizer Requests Depo-Provera Lawsuit Coordination as Mass Tort in Pennsylvania State Court (06/10/2025) Zantac Cancer Lawsuits Continue To Be Filed More Than 5 Years After Recall (Posted: 4 days ago) A man diagnosed with multiple forms of cancer has filed a Zantac lawsuit, blaming Boehringer Ingelheim for failing to adequately warn about the recalled heartburn drug’s health risks. MORE ABOUT: ZANTAC CANCER LAWSUITSJury Hears Zantac Cancer Evidence in Illinois Trial Against Boehringer Ingelheim (02/05/2025)Zantac Bladder Cancer Lawsuit Trial Ends With Hung Jury in California (11/22/2024)GSK To Pay $2.2 Billion To Settle Zantac Cancer Lawsuits Brought by 80,000 Consumers (10/10/2024) Enfamil NEC Lawsuit Filed After Newborn Suffers ‘Nearly Total Bowel Necrosis’ (Posted: 5 days ago) Necrotizing enterocolitis caused by Enfamil resulted in a newborn suffering life-long bowel injuries, according to a lawsuit filed by his mother. MORE ABOUT: ENFAMIL AND SIMILAC BABY FORMULA LAWSUITReckitt Benckiser Faces Class Action Lawsuit Over Enfamil NEC Risks (06/12/2025)NEC Infant Formula Lawyers To Meet With MDL Judge Following Dismissal of First Bellwether Trial (05/29/2025)FDA To Investigate Whether Infant Formula Products Provide Enough Nutrition (05/16/2025)
Boehringer Ingelheim Ordered to Pay $1.25M For Failure to Warn About Pradaxa Bleeding Risks October 25, 2018
Lawsuit Alleges Depo-Provera DMPA Injection Increases Brain Tumor Risks (Posted: 2 days ago) A Depo-Provera lawsuit blames the active ingredient, DMPA, for an increased risk of the development of brain tumors. MORE ABOUT: DEPO-PROVERA LAWSUITOrtho-Cept, Similar Birth Control Pills Linked to Intracranial Meningioma Risks, Study Warns (06/17/2025)Status of Depo-Provera Shot Lawsuits Outlined by MDL Judge (06/13/2025)Pfizer Requests Depo-Provera Lawsuit Coordination as Mass Tort in Pennsylvania State Court (06/10/2025)
Zantac Cancer Lawsuits Continue To Be Filed More Than 5 Years After Recall (Posted: 4 days ago) A man diagnosed with multiple forms of cancer has filed a Zantac lawsuit, blaming Boehringer Ingelheim for failing to adequately warn about the recalled heartburn drug’s health risks. MORE ABOUT: ZANTAC CANCER LAWSUITSJury Hears Zantac Cancer Evidence in Illinois Trial Against Boehringer Ingelheim (02/05/2025)Zantac Bladder Cancer Lawsuit Trial Ends With Hung Jury in California (11/22/2024)GSK To Pay $2.2 Billion To Settle Zantac Cancer Lawsuits Brought by 80,000 Consumers (10/10/2024)
Enfamil NEC Lawsuit Filed After Newborn Suffers ‘Nearly Total Bowel Necrosis’ (Posted: 5 days ago) Necrotizing enterocolitis caused by Enfamil resulted in a newborn suffering life-long bowel injuries, according to a lawsuit filed by his mother. MORE ABOUT: ENFAMIL AND SIMILAC BABY FORMULA LAWSUITReckitt Benckiser Faces Class Action Lawsuit Over Enfamil NEC Risks (06/12/2025)NEC Infant Formula Lawyers To Meet With MDL Judge Following Dismissal of First Bellwether Trial (05/29/2025)FDA To Investigate Whether Infant Formula Products Provide Enough Nutrition (05/16/2025)